This setback marks a major blow to AstraZeneca as it strives to lead the wave of PD-1–based BsAbs in the treatment of solid tumours across Western markets.
With regulatory conditions tightening around climate impact and environmental persistence of medical propellants, HFA-152a is a practical route to maintain clinical performance, patient outcomes and supply continuity of inhalers. However,...
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
Combine proprietary data, human expertise, and purpose-built AI to uncover insights and accelerate better business decisions.
Discover our solutions
Pharma Technology Focus is our digital magazine, free to read online on all devices. Click the magazine cover to read the latest issue. You can subscribe for free to have each new issue delivered to your inbox.
TrialAssure selected as EMA’s official clinical trial anonymisation partner
ASCO26: AI innovations show promise in reducing the oncology RWD burden
Keeping pace with generative AI in pharmaceutical and healthcare organisations
How wearables can unlock their full potential in clinical research